SPOTLIGHT: AstraZeneca, Par collaborate on authorized generic

AstraZeneca and Par Pharmaceutical have signed an agreement for Par to distribute an authorized generic version of AstraZeneca's Toporol (metoprolol succinate) in the U.S. Authorized generics represent branded pharma's response to the fierce competition they're facing from generic drug companies as a number of blockbuster drugs lose patent protection. Release

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.